Preliminary Study: The Relationship between Smoking History with ECOG Score, EGFR Mutation Status, and Clinicopathology Data of NSCLC Patients

Authors

DOI:

https://doi.org/10.36497/5wc3xm46

Keywords:

ECOG, EGFR mutation, Non-Small Cell Lung Carcinoma, Smoking history

Abstract

Background: Patients with non-small cell lung cancer (NSCLC) have a poor outcome. Mutations of the EGFR gene have a crucial role in determining therapy choices and prognosis. Smoking history, clinicopathological features, including patient performance, and EGFR gene mutation have served as clinical guidelines for monitoring. This study aims to examine the association between smoking history and ECOG score, EGFR mutation status, and clinicopathological characteristics of patients with NSCLC in Yogyakarta.

Methods: An observational and analytic study, with a retrospective cohort design from 32 patients diagnosed with NSCLC. Data on smoking history, clinicopathological characteristics, ECOG performance scores, and EGFR mutation types (Exon 19 deletion and Exon 21 L858R) were extracted and concluded from medical records. The relationship between these variables was analysed using the Chi-square test.

Results: The analysis began by exploring the relationship between smoking history and initial ECOG performance scores. It was discovered that non-smokers exhibited poorer initial ECOG scores (p = 0.025). Smoking history was significantly associated with specific EGFR mutation types (p = 0.009), although it showed no association with overall EGFR mutation status. The analysis revealed that deletions on Exon 19 were mainly found in patients who smoked, whereas mutations in Exon 21 were uniquely present in non-smokers. Clinical follow-up also shows an association (p = 0,002). This finding suggests that smoking behaviour interferes with the carcinogenesis of NSCLC.

Conclusion: The relationship between smoking history, performance status, exon-specific EGFR mutations, and clinical follow-up suggests differences in the carcinogenic mechanisms of NSCLC exon-specific mutations, highlighting biological diversity and emphasizing the need for detailed molecular studies to improve prognostic accuracy.

Downloads

Download data is not yet available.

Author Biographies

  • Dr. Charis Amarantini, M.Si, Universitas Kristen Duta Wacana

    Department of Biology, Faculty of Biotechnology, Universitas Kristen Duta Wacana, Yogyakarta, Indonesia

  • dr. Lili Ananta Saputra, SpPA, Universitas Kristen Duta Wacana / Bethesda Hospital

    Section of Anatomic Pathology, Faculty of Medicine, Universitas Kristen Duta Wacana, Yogyakarta, Indonesia

    Anatomic Pathology Laboratory, Bethesda Hospital, Yogyakarta, Indonesia

  • dr. Johana Puspasari Dwi Pratiwi. M.Sc, Universitas Kristen Duta Wacana

    Section of Histology, Faculty of Medicine, Universitas Kristen Duta Wacana, Yogyakarta, Indonesia

  • dr. Fransiska Galuh Widowati. M.Biomed, Universitas Kristen Duta Wacana

    Section of Anatomic Pathology, Faculty of Medicine, Universitas Kristen Duta Wacana, Yogyakarta, Indonesia

References

1. Abbasian, M. H., Ardekani, A. M., Sobhani, N., & Roudi, R. The role of genomics and proteomics in lung cancer early detection and treatment. Cancers. 2022;14:5144. https://doi.org/10.3390/CANCERS14205144

2. Huang, L., Liu, Y., Yi, C., et al. Pathological findings of pulmonary papillary adenoma with EGFR mutation and literature review: two cases report. J. Cardiothorac. Surg. 2024; 19(1):1–6. https://doi.org/10.1186/S13019-024-02852-2/FIGURES/3

3. Zheng, H., Zhang, Y., Zhan, Y., Liu, S., Lu, J., Feng, J.,et al. Prognostic analysis of patients with mutant and wild-type EGFR gene lung adenocarcinoma. Cancer Management and Research.2019;11:6139–6150. https://doi.org/10.2147/CMAR.S200126

4. Syahruddin, E., Soeroso, N. N., Ananda, F. R., Wulandari, L., Setijadi, A. R., Ermayanti, S., et al. The time to progression in lung adenocarcinoma patients receiving first- and second-generation EGFR-TKI in Indonesia. Jurnal Respirasi. 2025;11(1):22–30. https://doi.org/10.20473/jr.v11-i.1.2025.22-30

5. Tseng, C. H., Chiang, C. J., Tseng, J. Sen, Yang, T. Y., Hsu, K. H., Chen, K. C., et al. EGFR mutation, smoking, and gender in advanced lung adenocarcinoma. Oncotarget, 2017;8(58). https://doi.org/10.18632/oncotarget.21842

6. Datta SS, Ghosal N, Daruvala R, Chakraborty S, Shrimali RK, van Zanten C, et al. How do clinicians rate patient’s performance status using the ECOG performance scale? A mixed-methods exploration of variability in decision-making in oncology. Ecancer.2019,13, 913.

7. Chang, C. Y., Chen, C. Y., Chang, S. C., Lai, Y. C., & Wei, Y. F. Efficacy and prognosis of first-line egfr-tyrosine kinase inhibitor treatment in older adults including poor performance status patients with egfr-mutated non-small-cell lung cancer. Cancer Management and Research,2021;13:7187–7201. https://doi.org/10.2147/CMAR.S322967

8. Sekihara, K., Kawase, A., Matsubayashi, Y., Tajiri, T., Shibata, M., Hayakawa, T., et al. Impact of smoking on resected lung cancer depends on epidermal growth factor receptor mutation. Interdiscip Cardiovasc Thorac Surg.2024;39(1): ivae109. doi: 10.1093/icvts/ivae109.

9. Ying X, Freedland KE, Powell LH, Stuart EA, Ehrhardt S, Mayo-Wilson E. Determining sample size for pilot trials: a tutorial. BMJ.2026. [cited 2026 Jan 5]; Available from: https://www.bmj.com/

10. Zhang, Y., Kang, S., Fang, W., Hong, S., Liang, W., Yan, Y., Qin, T., Tang, Y., Sheng, J., & Zhang, L. Impact of smoking status on EGFR-TKI efficacy for advanced non-small-cell lung cancer in EGFR mutants: A meta-analysis. Clinical Lung Cancer. 2015;16(2), 144-151.e1. https://doi.org/10.1016/j.cllc.2014.09.008

11. Popat, S., Liu, S. V., Scheuer, N., Gupta, A., Hsu, G. G., Ramagopalan, S. V., et al. Association between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced Non-Small Cell Lung Cancer. JAMA Network Open. 2022 5(5): e2214046. https://doi.org/10.1001/jamanetworkopen.2022.14046

12. Shen, C. H., & Yang, L. Y. The association between postdiagnosis smoking cessation and survival in advanced non-small cell lung cancer patients in Southern Taiwan: A retrospective cohort study. Tzu Chi Medical Journal. 2025;37(2):211–215. https://doi.org/10.4103/tcmj.tcmj_109_24

13. Wang, X., Ricciuti, B., Alessi, J. V., Nguyen, T., Awad, M. M., Lin, X., et al. Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer. Journal of the National Cancer Institute.2021;113(12):1761–1769. https://doi.org/10.1093/jnci/djab116

14. Wicaksono, A., & Putra, A. C. The Impact of Smoking Degree on One Year Survival of Non-Small Cell Lung Cancer (NSCLC) at Persahabatan Hospital. Jurnal Epidemiologi Kesehatan Indonesia. 2024;8(2). https://doi.org/10.7454/epidkes.v8i2.1110

15. Jiang, H., Zhu, M., Li, Y., & Li, Q. Association between egfr exon 19 or exon 21 mutations and survival rates after first-line egfr‑tki treatment in patients with non-small cell lung cancer. Molecular and Clinical Oncology. 2019;11(3), 301–308. https://doi.org/10.3892/mco.2019.1881

16. Dawe, D. E., Rittberg, R., Syed, I., Shanahan, M. K., Moldaver, D., Bucher, O., et al. Real-world predictors of survival in patients with limited-stage small-cell lung cancer in Manitoba, Canada. Frontiers in Oncology. 2023;13(December),1–13. https://doi.org/10.3389/fonc.2023.1191920

17. Kim, S. Y., Myung, J. K., Kim, H. R., Na, I. Il, Koh, J. S., Baek, H. J., et al. Factors that predict clinical benefit of EGFR TKI therapy in patients with EGFR wild-type lung adenocarcinoma. Tuberculosis and Respiratory Diseases. 2019;82(1),62–70. https://doi.org/10.4046/trd.2018.0004

18. Nagl, L., Pall, G., Wolf, D., Pircher, A., & Horvath, L. Molecular profiling in lung cancer. Memo - Magazine of European Medical Oncology. 2022;15(3),201–205. https://doi.org/10.1007/s12254-022-00824-7

19. Karachaliou, N., Fernandez-Bruno, M., Bracht, J. W. P., & Rosell, R. EGFR first- and second-generation TKIs-there is still place for them in EGFR-mutant NSCLC patients. Translational Cancer Research. 2019;8(Suppl 1), S23–S47. https://doi.org/10.21037/tcr.2018.10.06

20. Armocida, D., Pesce, A., Palmieri, M., Cofano, F., Palmieri, G., Cassoni, P, et al. EGFR-Driven Mutation in Non-Small-Cell Lung Cancer (NSCLC) Influences the Features and Outcome of Brain Metastases. Journal of Clinical Medicine. 2023;12(10), 1–13. https://doi.org/10.3390/jcm12103372

21. Qi, H., Qiao, Q., Sun, X., & Xing, L. Survival Outcomes in EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases: Kaplan–Meier and Cox Regression Analyses Across Treatment Stages. Clinical Respiratory Journal. 2025;19(5), 1–13. https://doi.org/10.1111/crj.70085

22. Marino, F. Z., Bianco, R., Accardo, M., Ronchi, A., Cozzolino, I., Morgillo, F., et al. Molecular heterogeneity in lung cancer: From mechanisms of origin to clinical implications. International Journal of Medical Sciences. 2019; 16(7), 981–989. https://doi.org/10.7150/ijms.34739

23. Passaro, A., Malapelle, U., Del Re, M., Attili, I., Russo, A., Guerini-Rocco, E., et al. Understanding EGFR heterogeneity in lung cancer. ESMO Open. 2020;5(5), e000919. https://doi.org/10.1136/ESMOOPEN-2020-000919

24. Testa, U., Castelli, G., & Pelosi, E. Lung cancers: Molecular characterization, clonal heterogeneity and evolution, and cancer stem cells. Cancers. 2018;10(8), 1–81. https://doi.org/10.3390/cancers10080248

25. Jiang, D. D., Wang, Z. X., Li, H. Y., Liu, J. M., Cui, M. L., & Luo, Y. X. Experiences of patient delay among lung cancer patients in South China. BMC Cancer. 2024;24(1). https://doi.org/10.1186/s12885-024-13295-2

26. Asmara, O. D., Tenda, E. D., Singh, G., Pitoyo, C. W., Rumende, C. M., Rajabto, W., et al. Lung Cancer in Indonesia. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer. 2023;18(9), 1134–1145. https://doi.org/10.1016/J.JTHO.2023.06.010

27. Chen, Z.-Y., Zhong, W.-Z., Zhang, X.-C., Su, J., Yang, X.-N., Chen, Z.-H., et al. EGFR Mutation Heterogeneity and the Mixed Response to EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinomas . The Oncologist. 2012;17(7), 978–985. https://doi.org/10.1634/theoncologist.2011-0385

28. Aye, P. S., McKeage, M. J., Tin Tin, S., Khwaounjoo, P., & Elwood, J. M. Factors associated with overall survival in a population-based cohort of non- squamous NSCLC patients from northern New Zealand: A comparative analysis by EGFR mutation status. Cancer Epidemiology. 2020; 69, 101847. https://doi.org/10.1016/j.canep.2020.101847

29. Steuer, C. E., Jegede, O. A., Dahlberg, S. E., Wakelee, H. A., Keller, S. M., Tester, W. J., et al. Smoking Behavior in Patients With Early-Stage NSCLC: A Report From ECOG-ACRIN 1505 Trial. Journal of Thoracic Oncology. 2021;16(6), 960–967. https://doi.org/10.1016/j.jtho.2020.12.017

Published

2026-01-31

Issue

Vol. 46 No. 1 (2026)

Section

Original Article

License

Copyright (c) 2026 dr. Tejo Jayadi, SpPA, Dr. Charis Amarantini, M.Si, dr. Lili Ananta Saputra, SpPA, dr. Johana Puspasari Dwi Pratiwi. M.Sc, dr. Fransiska Galuh Widowati. M.Biomed

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

  1. The authors own the copyright of published articles. Nevertheless, Jurnal Respirologi Indonesia has the first-to-publish license for the publication material.
  2. Jurnal Respirologi Indonesia has the right to archive, change the format and republish published articles by presenting the authors’ names.
  3. Articles are published electronically for open access and online for educational, research, and archiving purposes. Jurnal Respirologi Indonesia is not responsible for any copyright issues that might emerge from using any article except for the previous three purposes.

How to Cite

Preliminary Study: The Relationship between Smoking History with ECOG Score, EGFR Mutation Status, and Clinicopathology Data of NSCLC Patients. (2026). Jurnal Respirologi Indonesia, 46(1). https://doi.org/10.36497/5wc3xm46

Similar Articles

1-10 of 192

You may also start an advanced similarity search for this article.